NSABP FC-9
Select A Category

NSABP FC-9

A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab (MEDI4736) plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy

Primary Objective: To determine the efficacy of the dual immune checkpoint blockade with durvalumab plus tremelimumab following a small dose of hypofractionated palliative radiation in patients with MSS mCRC who have progressed on chemotherapy

Patient Population: patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who have progressed on chemotherapy

Target Accrual: 21 patients

Status: closed to accrual

ClinicalTrials.gov Identifier: NCT03007407